In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo- β-lactamases–co-producing carbapenem-resistant Enterobacter cloacae complex

ConclusionTo our knowledge, this study represents the first report on the in vitro and in vivo antibacterial activity of CZA plus ATM against CRECC isolates co-harboringmcr-9, MBL and TEM. Our findings suggest that the combination regimen of CZA  + ATM provides a valuable reference for clinicians to address the increasingly complex antibiotic resistance situation observed in clinical microorganisms.
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research